Navigation Links
Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
Date:10/30/2008

JERUSALEM, October 30 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that its Chief Executive Officer, Mr. Nadav Kidron, will be giving a company presentation at the 10th Annual Rodman & Renshaw Healthcare Conference at New York City's Palace Hotel on November 11. Mr. Kidron is scheduled to present from 4:05 - 4:30 in the Kennedy II Ballroom, located on the 4th floor of the hotel.

"The Rodman & Renshaw Conference will give Oramed an important platform to present the accomplishments we have achieved in our development of an oral insulin capsule and our unique position as a technology pioneer in the field of oral delivery solutions," said Kidron.

For more information about Rodman & Renshaw and the upcoming conference, please visit http://www.rodmanandrenshaw.com/conferences.

For more information about Oramed Pharmaceuticals, please visit http://www.oramed.com.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals

Eric Rosenberg

Cell: +972-54-566-7713

Office: +972-2-566-0001

Email: eric@oramed.com

Media Contacts:

Ruder Finn Israel for Oramed

Matthew Krieger

Cell: +972-54-467-6950

Office: +972-2-589-2003

Email: matthew@oramed.com


'/>"/>
SOURCE Oramed Pharmaceticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
4. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
6. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
7. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
8. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
9. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
10. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
11. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... London, June 28, 2017 (PRWEB) , ... ... ... The latest release of Siemens’ STAR-CCM+® software for multiphysics computational fluid dynamics ... automated product design exploration and optimization. STAR-CCM+ version 12.04 introduces Design Manager, ...
(Date:6/28/2017)... ... 28, 2017 , ... Studies indicate that replacing damaged brain cells with those ... disease. But what has not been determined is the optimal stage during differentiation of ... , A new study coming out of Singapore, recently published in STEM CELLS Translational ...
(Date:6/27/2017)... AZ (PRWEB) , ... June 27, 2017 , ... ... world’s first brain mirroring wellness product via Kickstarter campaign on June 15th to ... have already pre-ordered the B2v2, exceeding the original Kickstarter goal by more than ...
(Date:6/27/2017)... ... 27, 2017 , ... According to a recent report from ... not have negative short- or long-term effects on benthic communities. , The ... located at the Puget Sound Naval Shipyard & Intermediate Maintenance Facility in Bremerton, ...
Breaking Biology Technology:
(Date:5/23/2017)... GENOA, Italy , May 23, 2017  Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):